Connect with us


Innoup receives €500,000 from the Government to develop a vaccine against COVID-19

The company Innoup from Navarra has obtained a grant from the Center for the Development of Industrial Technology to implement a vaccine based on nanoparticles. Innoup joined other Spanish companies that have received government funding, such as Touchlight. The Basque company also received $591,000 (€500,000) to develop a platform for the rapid production of adeno-associated virus (AAV) vaccine.



This picture show a city during twilight.

Innoup also joins the list of companies working in research and development in the fight against coronavirus. The company from Navarra, specialized in the development of therapies to fight breast cancer and food allergies, has received $591,000 (€500,000) from the Government, as explained by the management of the company. 

The company will use the funding to develop a new vaccine based on nanoparticles with Sars-Cov-2 inactivated for administration in mucous membranes, as commented by the Spanish startup. Innoup, based in the town of Noain, Navarra, has obtained funding from the Center for the Development of Industrial Technology (Cdti), belonging to the Ministry of Science and Innovation, to help combat the coronavirus pandemic.

If you want to find more details about the biotech company Innoup from Spain and why it received half a million euros from the Government, download for free the Born2Invest mobile app. Read the most important business headlines in the world with our companion app, available for both Android and iOS devices.

The company focuses on two innovative drugs

Innoup is a biopharmaceutical company dedicated to nanotechnology innovation that develops innovative, safer, and more effective drugs for the treatment of diseases for which there is currently no cure. Innoup is focused on two medicines, one for peanut allergy, and the other for treatment for breast cancer. 

The company bets on its vaccination adjuvant, that is, that some nanoparticles can be introduced with a substance that can act as a vaccine. Innoup makes available its technology to other major groups to advance research. In fact, the company is also focused on the development of two drugs: INP20, a vaccine for peanut allergy, and INP12, an oral treatment for breast cancer. 

Innoup was funded in 2013 from a research group specialized in nanomedicine from the University of Navarra. Maite Agüeros is the CEO of the company, PhD in Pharmacy and holds a Master in Business Administration and Management, as well as research experience in the area of nanomedicine. Manuel Rodríguez is the CEO and has more than 25 years of experience in the pharmaceutical sector in companies such as Almirall and Novartis. In addition to Agüeros and Rodríguez, the company has Juan Manuel Irache as a director and advisor. Irache has worked in different European universities and was President of the Spanish Society of Industrial Pharmacy. 

Innoup is not the only Spanish company to receive funding from the Government

Innoup joined other Spanish companies that have received government funding, such as Touchlight. The Basque company also received $591,000 (€500,000) to develop a platform for the rapid production of adeno-associated virus (AAV) vaccines based on dbDNA against COVID-19

This company is working on a vaccine project that is sponsored by the Massachusetts Eye and Ear Hospital research center in Boston. Another company that received Cdti’s support was Operon. The Aragonese company, which manufactures rapid tests for human diagnosis, food, and veterinary analysis, obtained half a million euros in the summer to finance research into rapid antibody tests and nose and throat tests for coronavirus.


(Featured image by Aleksandar Pasaric via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Desmond O’Flynn believes in minimalism and the power of beer. As a young reporter for some of the largest national publications, he has lived in the world of finance and investing for nearly three decades. He has since included world politics and the global economy in his portfolio. He also writes about entrepreneurs and small businesses, as well as innovation in fintech, gambling, and cannabis industries.